Literature DB >> 17564728

Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis.

Carlos J Cobeñas1, Laura F Alconcher, Ana P Spizzirri, Ricardo C Rahman.   

Abstract

We examined the records of patients with hemolytic uremic syndrome, who had not undergone dialysis during the acute stage, with the aims of evaluating: (1) the outcome after at least 5 years of follow-up; (2) the value of peak serum creatinine as a prognostic marker; (3) the relationship between outcome and time to normalization of renal function. From 1968 to 2000, 1,179 patients were assisted. Forty-two patients (3.6%) died during the acute stage, 478 patients (40.5%) required dialysis and 659 patients (55.9%) did not undergo dialysis; 529 non-dialysis patients were lost to follow-up. The remaining 130 patients were classified into four groups: group I, complete recovery; group II, with two subgroups, IIa, microalbuminuria, and IIb, proteinuria and/or high blood pressure, both with normal renal function; group III, chronic renal failure; and group IV, end-stage renal disease. We analyzed the relationship between final outcome and: (1) peak creatinine (the highest of at least two determinations) during the acute stage and (2) time to normalization of urea and/or creatinine after the acute stage. After a mean follow-up time of 147.1 months (range 60-362 months), group I had 83 patients (63.9%), group IIa had 27 (20.8%), group IIb had 15 (11.5%) and group III had 5 (3.8%). The value of peak serum creatinine concentration was available for 57 patients. On the last clinical visit, eight out of 26 (30.7%) patients with peak serum creatinine equal to or higher than 1.5 mg/dl were in groups IIb and III versus one out of 31 (3.2%) patients with lower values (P < or = 0.007). Finally, six out of 28 patients (21%) whose renal function had normalized after 15 days from diagnosis were in groups IIb-III versus 8/82 (9.7%) whose renal function had normalized within 15 days (P = 0.18). After a mean period of follow-up of 12 years, 15% of a selected patient group had developed proteinuria, high blood pressure or chronic renal failure, and 21% had developed microalbuminuria. Peak serum creatinine during the acute stage was useful as a prognostic indicator. Patients whose renal function required more time to normalize did not have a worse outcome.

Entities:  

Mesh:

Year:  2007        PMID: 17564728     DOI: 10.1007/s00467-007-0522-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

1.  THE HEMOLYTIC-UREMIC SYNDROME.

Authors:  C GIANANTONIO; M VITACCO; F MENDILAHARZU; A RUTTY; J MENDILAHARZU
Journal:  J Pediatr       Date:  1964-04       Impact factor: 4.406

2.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

3.  Epidemic hemolytic-uremic syndrome in children.

Authors:  H A Repetto
Journal:  Kidney Int       Date:  1997-12       Impact factor: 10.612

4.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

Review 5.  Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome.

Authors:  Horatio A Repetto
Journal:  Kidney Int Suppl       Date:  2005-08       Impact factor: 10.545

6.  Haemolytic uraemic syndrome associated with faecal cytotoxin and verotoxin neutralizing antibodies.

Authors:  A A Novillo; L E Voyer; R Cravioto; M C Freire; G Castaño; R Wainstein; N Binztein
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

7.  Management of patients with hemolytic uremic syndrome demonstrating severe azotemia but not anuria.

Authors:  S L Schulman; B S Kaplan
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

8.  Microalbuminuria three years after recovery from Escherichia coli O157 hemolytic uremic syndrome due to municipal water contamination.

Authors:  Amit X Garg; William F Clark; Marina Salvadori; Jennifer Macnab; Rita S Suri; R Brian Haynes; Douglas Matsell
Journal:  Kidney Int       Date:  2005-04       Impact factor: 10.612

9.  Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features.

Authors:  F D Spizzirri; R C Rahman; N Bibiloni; J D Ruscasso; O R Amoreo
Journal:  Pediatr Nephrol       Date:  1997-04       Impact factor: 3.714

10.  Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome.

Authors:  M F Gagnadoux; R Habib; M C Gubler; J L Bacri; M Broyer
Journal:  Clin Nephrol       Date:  1996-07       Impact factor: 0.975

View more
  14 in total

1.  Introduction: education teaching article series on hemolytic uremic syndrome.

Authors:  Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2008-06-06       Impact factor: 3.714

Review 2.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

3.  Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome.

Authors:  Carlos J Cobeñas; Paula S Bresso; Laura L Lombardi; Oscar R Amoreo; Javier D Ruscasso; Ana P Spizzirri; Ângela Del C Suarez; Javier H Zalba; Ricardo C Rahman; Paula Risso
Journal:  Pediatr Nephrol       Date:  2015-07-04       Impact factor: 3.714

4.  Atypical hemolytic-uremic syndrome (HUS) with recovery after a long-lasting anuria: a case report.

Authors:  H Georgaki-Angelaki; N Stergiou; A Kapogiannis; I Orfanou; B Grapsa; E Roma
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

5.  Methods for characterizing differences in longitudinal glomerular filtration rate changes between children with glomerular chronic kidney disease and those with nonglomerular chronic kidney disease.

Authors:  Christopher B Pierce; Christopher Cox; Jeffrey M Saland; Susan L Furth; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2011-08-09       Impact factor: 4.897

6.  Clinical characteristics of children with hemolytic uremic syndrome in Hangzhou, China.

Authors:  Shui-Ai Zhao; Bo-Tao Ning; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2017-03-28       Impact factor: 2.764

7.  Levels of urinary transforming growth factor beta-1 in children with D+ hemolytic uremic syndrome.

Authors:  María Gracia Caletti; Alejandro Balestracci; Adriana Haydeé Roy
Journal:  Pediatr Nephrol       Date:  2010-02-16       Impact factor: 3.714

Review 8.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

Review 9.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

Review 10.  Subtyping of STEC by MLVA in Argentina.

Authors:  Ana V Bustamante; Andrea M Sanso; Alberto E Parma; Paula M A Lucchesi
Journal:  Front Cell Infect Microbiol       Date:  2012-08-22       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.